World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

Login Register
World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

SJIF Impact Factor: 6.842

Abstract

TRASTUZUMAB AS MONOCLONAL ANTIBODY; INHIBITOR OF HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR-2 PROTEIN KINASE FOR BREAST CANCER

*Dr. Dhrubo Jyoti Sen, Dr. Pruthviraj K. Chaudhary and Shloka Vijaykumar Chaudhary

ABSTRACT

Trastuzumab is a targeted (biological) therapy. Targeted therapies block the growth and spread of cancer. They target and interfere with processes in the cells that help cancer grow. It is a biologic agent primarily used to treat HER2-positive breast cancer and may be used as adjuvant therapy for localized disease or as first-line treatment for metastatic disease. The inhibition of the hyperactive HER2 protein kinase receptor by trastuzumab in HER2+ breast cancer cells can be partly considered an immunotherapy strategy, since the monoclonal antibody (mAb) mechanism of action includes an immune-mediated component. HER2-positive breast cancer is a breast cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). This protein promotes the growth of cancer cells.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR